Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Entertainment Now
Spring Wellness
Home & Garden
Home Improvement
Home & Realty
Outdoor Guide
Women
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Services
Readersâ Choice
Auction
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ocular Therapeut
(NQ:
OCUL
)
7.610
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 8, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
57
Open
7.610
Bid (Size)
7.500 (8)
Ask (Size)
7.750 (3)
Prev. Close
7.610
Today's Range
7.610 - 7.610
52wk Range
2.570 - 7.740
Shares Outstanding
77,524,666
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Expert Ratings for Ocular Therapeutix
May 09, 2023
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
May 09, 2023
Via
Benzinga
Performance
YTD
+172.76%
+172.76%
1 Month
+16.18%
+16.18%
3 Month
+44.13%
+44.13%
6 Month
+175.72%
+175.72%
1 Year
+95.13%
+95.13%
More News
Read More
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments
May 02, 2023
Via
FinancialNewsMedia
Exposures
COVID-19
What 5 Analyst Ratings Have To Say About Ocular Therapeutix
April 21, 2023
Via
Benzinga
Looking Into Ocular Therapeutix's Return On Capital Employed
March 09, 2023
Via
Benzinga
The Latest Analyst Ratings for Ocular Therapeutix
March 07, 2023
Via
Benzinga
Earnings Outlook For Ocular Therapeutix
March 03, 2023
Via
Benzinga
Why Shares of Ocular Therapeutix Jumped This Week
February 16, 2023
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For April 21, 2023
April 21, 2023
Via
Benzinga
OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay
April 18, 2023
Via
Benzinga
OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4
March 28, 2023
Via
Benzinga
Dick's Sporting Goods, WW International, Sea Limited And Other Big Stocks Moving Higher On Tuesday
March 07, 2023
Via
Benzinga
Tesla, Solaredge, Palantir, Cleveland-Cliffs, Ocular Therapeutix: Why These 5 Stocks Are Drawing Heavy Attention Today
February 13, 2023
Via
Benzinga
Dow Gains Over 300 Points; S&P 500 Up 1%
February 13, 2023
Via
Benzinga
Why Frequency Therapeutics Are Trading Lower By 82%? Here Are Other Stocks Moving In Monday's Mid-Day Session
February 13, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
February 13, 2023
Via
Benzinga
Nasdaq Rises 1.5%; G1 Therapeutics Shares Plummet
February 13, 2023
Via
Benzinga
Teradata, Monday.Com And Other Big Stocks Moving Higher On Monday
February 13, 2023
Via
Benzinga
US Stocks Open Higher; Dow Jumps 200 Points
February 13, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
February 13, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
February 13, 2023
Via
InvestorPlace
Ocular Therapeutix Shares Jump On Favorable Data From Intravitreal Implant Study In Wet AMD
February 13, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
December 12, 2022
Via
Benzinga
AiViva Reports That Their Promising New Treatment For Wet AMD Is Soon To Be Ready For Clinical Trials
November 14, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
December 08, 2022
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.